MBX (MBX Biosciences, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings
MBX Biosciences, Inc. Common Stock (MBX) is a publicly traded Healthcare sector company. As of May 20, 2026, MBX trades at $31.45 with a market cap of $1.47B and a P/E ratio of -13.25. MBX moved +3.31% today. Year to date, MBX is +7.23%; over the trailing twelve months it is +154.29%. Its 52-week range spans $4.81 to $45.85. Analyst consensus is strong buy with an average price target of $73.11. Rallies surfaces MBX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Who owns MBX stock?
Hedge funds tracked by Rallies that own MBX include Orbimed Advisors and Soros Fund. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for MBX Biosciences, Inc. Common Stock.
MBX Key Metrics
Key financial metrics for MBX
Metric
Value
Price
$31.45
Market Cap
$1.47B
P/E Ratio
-13.25
EPS
$-2.38
Dividend Yield
0.00%
52-Week High
$45.85
52-Week Low
$4.81
Volume
757.13K
Avg Volume
0
Revenue (TTM)
$0
Net Income
$-86.97M
Gross Margin
0.00%
Top Hedge Funds Holding MBX
Orbimed Advisors holds 3.64M shares of MBX, changed -7.56% as of Mar 31, 2026.
Soros Fund holds 30.00K shares of MBX, changed +0.00% as of Sep 30, 2024.
Hedge funds tracked by Rallies that own MBX include Orbimed Advisors and Soros Fund. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for MBX Biosciences, Inc. Common Stock.
Does Rallies show 13F holders for MBX?
Yes. Rallies tracks hedge fund and 13F ownership data for MBX, including fund names, share counts, latest tracked quarter, and position changes when available.
Is MBX research on Rallies investment advice?
No. Rallies provides research, data, and educational context for MBX. It does not provide personalized investment advice.
